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In this population-based Norwegian cohort study (2.1 million children), the impact of birth and parental characteristics on the risk of
neuroblastoma (178 cases) was evaluated. In children below the age of 18 months, there was an increased neuroblastoma risk among
those with congenital malformations and suggestion of increased risk when the mother had pre-eclampsia.
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Neuroblastoma is the most common cancer in children less than 1
year of age, and is the third most common malignancy in childhood
(below 5 years of age) in the United States (Goodman et al, 1999).
The incidence of neuroblastoma has increased in some European
countries during 1978–1997 (Kaatsch et al, 2006; Spix et al, 2006),
possibly influenced by changes in identification and reporting of
the disease over time. Although there has been substantial
improvement in prognosis of well-defined subsets of patients in
the past few decades, the long-term survival for children with high-
risk disease is still less than 40% (Maris et al, 2007).
Neuroblastoma is an embryonal tumour that originates from
primordial neural crest cells that eventually develop into the
sympathetic nervous system (SNS) and the adrenal medulla. The
tumour almost exclusively occurs in infants and young children.
About 50% of the tumours originate in the adrenal gland, another
20% in other areas of the abdomen and about 30% in the
sympathetic ganglia in the neck, thorax and pelvis (Huddart and
Mann, 1991; Buck et al, 2001). The most frequent genetic
abnormality found in neuroblastoma is the amplification of the
MYCN protooncogene, but also other genetic abnormalities have
been identified (Maris et al, 2007).
Relatively little is known about the aetiology of neuroblastoma.
The peak incidence during early childhood indicates that prenatal
and perinatal factors may play an important role in its
pathogenesis, but the evidence is rather limited and inconclusive
(Hamrick et al, 2001; Schuz et al, 2001). In this study, we aimed to
evaluate the impact of birth and parental characteristics on the risk
of neuroblastoma, both adrenal and non-adrenal, in a large
population-based Norwegian cohort study, using data from the
medical birth and cancer registries of Norway.
MATERIALS AND METHODS
Study subjects
The Medical Birth Registry of Norway (MBRN) is population-
based and contains information on all births in Norway since 1967,
defined as all live births and reported foetal deaths of 16
complete weeks of gestation or more. Each record contains
information on demographic variables, pregnancy, delivery
and the newborn (Irgens, 2000). Data on all deaths registered
by Statistics Norway are routinely linked to the birth records.
Medical Birth Registry of Norway includes a unique identification
number assigned to all live-born children in Norway as well as
parents.
Since 1953, the Cancer Registry of Norway (CRN) has received
information on all cancer patients in the population. The reporting
system is based on pathology and cytology reports, clinical records
and death certificates, and provides information about site,
histological type and stage of disease at the time of diagnosis
(The Cancer Registry of Norway, 2008). Through 1992, registration
was based on a modified version of ICD-7. Since 1993, ICD-O has
been the basis for coding.
All live-born children in Norway during the period 1967–2004
(n¼2127452) were defined as our study cohort. However,
twins, triplets and quadruplets were excluded from the
analyses. The personal identification number was used to link
the two registries to identify all cases of neuroblastoma in
children below 15 years of age. For each child, only the first
histologically verified malignant tumour was included in the
study. All histologically confirmed neuroblastoma in the SNS were
included. Neuroblastomas in the central nervous system
and in the eye were excluded. Ganglioneuroblastoma and
ganglioneuromas were excluded as well. Each person was
followed up from date of birth until 15 years of age, emigration,
cancer diagnosis (any site), death or until 31 December 2004.
Screening for neuroblastoma has never been introduced in
Norway.
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yTable 1 Relative risk (RR) of neuroblastoma (adrenal and non-adrenal) with 95% confidence intervals (CIs) obtained in Cox regression analyses with age
as the time variable, univariate
Adrenal medulla Non-adrenal All
Total no. of
N RR (95% CI) N RR (95% CI) N RR (95% CI) person-years
a
Sex
Male 44 1.0 Referent 50 1.0 Referent 94 1.0 Referent 12986975
Female 39 0.9 (0.6–1.4) 45 1.0 (0.6–1.4) 84 0.9 (0.7–1.3) 12315885
Season of birth
Winter 19 1.0 Referent 22 1.0 Referent 41 1.0 Referent 6055108
Spring 21 1.0 (0.5–1.8) 22 0.9 (0.5–1.6) 43 0.9 (0.6–1.4) 6948415
Summer 14 0.7 (0.3–1.4) 32 1.4 (0.8–2.4) 46 1.1 (0.7–1.6) 6377263
Autumn 29 1.6 (0.9–2.8) 19 0.9 (0.5–1.6) 48 1.2 (0.8–1.8) 5922074
Birth year
1967–1976 15 1.0 Referent 34 1.0 Referent 49 1.0 Referent 9048742
1977–1986 31 2.5 (1.4–4.7) 22 0.8 (0.5–1.4) 53 1.3 (0.9–2.0) 7367257
1987–1996 23 1.6 (0.9–3.1) 24 0.8 (0.5–1.3) 47 1.0 (0.7–1.5) 7103214
1997–2004 14 1.7 (0.8–3.6) 15 0.9 (0.5–1.6) 29 1.1 (0.7–1.8) 1783647
Test for trend P¼0.07 P¼0.4 P¼0.5
Gestational age (weeks)
o37 3 0.8 (0.3–2.7) 2 0.5 (0.1–2.0) 5 0.6 (0.3–1.6) 1093431
37–39 25 1.0 (0.6–1.6) 27 1.0 (0.6–1.5) 52 1.0 (0.7–1.4) 7533126
40–41 38 1.0 Referent 43 1.0 Referent 81 1.0 Referent 11698199
42+ 16 1.5 (0.8–2.7) 14 1.2 (0.6–2.1) 30 1.3 (0.9–2.0) 3376235
Test for trend P¼0.6 P¼0.2 P¼0.2
Birth weight (g)
500–2499 3 1.3 (0.4–4.5) 0 0.0 (0.0-) 3 0.6 (0.2–1.9) 803494
2500–2999 8 1.1 (0.5–2.5) 11 1.2 (0.6–2.4) 19 1.2 (0.7–2.0) 2645261
3000–3499 22 1.0 Referent 28 1.0 Referent 50 1.0 Referent 8110752
3500–3999 32 1.3 (0.8–2.2) 36 1.1 (0.7–1.9) 68 1.2 (0.8–1.7) 8993123
4000–4499 15 1.4 (0.7–2.7) 18 1.3 (0.7–2.4) 33 1.4 (0.9–2.1) 3832887
4500–6300 2 0.8 (0.2–3.4) 1 0.3 (0.0–2.3) 3 0.5 (0.2–1.7) 869990
Test for trend P¼0.6 P¼0.6 P¼0.5
Birth length (cm)
40–49 22 0.6 (0.4–1.2) 25 0.8 (0.5–1.5) 47 0.7 (0.5–1.1) 7514368
50 23 1.0 Referent 20 1.0 Referent 43 1.0 Referent 5127381
51 7 0.3 (0.1–0.8) 21 1.2 (0.6–2.2) 28 0.7 (0.5–1.2) 4580532
52 13 0.8 (0.4–1.6) 13 0.9 (0.5–1.8) 26 0.8 (0.5–1.4) 3634186
53–60 13 0.8 (0.4–1.5) 13 0.9 (0.4–1.8) 26 0.8 (0.5–1.3) 3823916
Test for trend P¼0.4 P¼0.4 P¼0.2
Head circumference (cm)
b
o35 18 1.1 (0.6–1.9) 19 1.2 (0.7–2.1) 37 1.1 (0.7–1.7) 4508997
35–36 30 1.0 Referent 29 1.0 Referent 59 1.0 Referent 7996344
37+ 17 1.5 (0.8–2.7) 12 1.1 (0.6–2.2) 29 1.3 (0.8–2.0) 2938088
Test for trend P¼0.3 P¼1.0 P¼0.5
Congenital malformations
No 78 1.0 Referent 92 1.0 Referent 170 1.0 Referent 24841001
Yes 5 3.2 (1.3–7.8) 3 1.6 (0.5–5.1) 8 2.3 (1.2–4.8) 461860
Maternal age (years)
o20 1 0.2 (0.0–1.6) 6 1.2 (0.5–2.9) 7 0.7 (0.3–1.6) 1326358
20–24 26 1.0 (0.6–1.7) 25 0.9 (0.5–1.5) 51 1.0 (0.7–1.4) 7229682
25–29 34 1.0 Referent 36 1.0 Referent 70 1.0 Referent 8916292
30–34 15 0.7 (0.4–1.2) 18 0.8 (0.4–1.4) 33 0.7 (0.5–1.1) 5394919
35+ 7 0.7 (0.3–1.6) 10 0.9 (0.5–1.9) 17 0.8 (0.5–1.4) 2419919
Test for trend P¼0.4 P¼0.6 P¼0.4
Parity
1 37 1.0 Referent 38 1.0 Referent 75 1.0 Referent 10431465
2–3 37 0.8 (0.5–1.3) 45 1.0 (0.6–1.5) 82 0.9 (0.6–1.2) 12803473
4–5 8 1.3 (0.6–2.9) 8 1.3 (0.6–2.8) 16 1.3 (0.8–2.3) 1712654
6+ 1 1.1 (0.2–8.3) 2 2.2 (0.5–9.2) 3 1.7 (0.5–5.4) 255223
Test for trend P¼0.8 P¼0.9 P¼0.9
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Cox proportional hazards regression models (Cox and Oakes,
1984), with time since birth as the time variable, were fitted to
obtain relative risk (RR) estimates of neuroblastoma. Tests for
trend in the risk of neuroblastoma were performed by including
the variables as continuous variables. In subanalyses, the study
cohort was stratified by age (below and above 18 months)
according to new risk stratification criteria (Maris et al, 2007).
The statistical package SPSS (SPSS Inc., 2006) was used for
estimating RRs of neuroblastoma with 95% confidence intervals
(CIs).
RESULTS
Altogether 2127452 children (1092727 boys and 1034725 girls)
were included in our study, comprising 25302860 person-years.
The mean time of follow-up was 11.9 years. A total of 178 children
(94 boys and 84 girls) were diagnosed with neuroblastoma during
1967–2004. The primary location of 83 tumours was in the adrenal
medulla, whereas 95 tumours were located at non-adrenal sites.
Ninety-seven cases (54%) were diagnosed before the age of 18
months, 62 cases between 18 months and 4 years, 15 cases between
5 and 9 years and four cases between 10 and 14 years. The number
of adrenal and non-adrenal cases was similar before 5 years of age,
thereafter there were more cases of non-adrenal origin.
Tables 1 and 2 show results from univariate analyses
investigating the relations between birth and parental character-
istics and risk of neuroblastoma. There was an increased risk
among children with congenital malformations (RR¼2.3, 95%
CI¼1.2–4.8). This increase was restricted to tumours of adrenal
origin (RR¼3.2, 95% CI¼1.3–7.8) and to children diagnosed
before the age of 18 months (RR¼3.7, 95% CI¼1.7–8.0). No
other specific association with birth and parental characteristics
was observed with regard to location of tumour (adrenal and non-
adrenal) (Table 1). Among children having mothers with
pre-eclampsia during pregnancy, six developed neuroblastoma
during follow-up (RR¼1.2, 95% CI¼0.5–2.8), all these
cases being diagnosed below 18 months of age (RR¼2.3, 95%
CI¼1.0–5.2).
Analyses of the study cohort stratified by age below and above
12 months did not reveal results substantially different from those
described above (data not shown).
DISCUSSION
Analyses of the relations between birth and parental characteristics
and the risk of neuroblastoma in a large Norwegian cohort
suggested that some of these factors may have an influence. In
children below the age of 18 months, there was an increased risk
among those with congenital malformations and also a suggestion
of increased risk when the mother had pre-eclampsia.
One of the major strengths of this study is the use of large health
registries, covering the total population of Norway, to get reliable
data on birth and parental characteristics and cancer occurrence.
Reporting of cancer cases to CRN has been compulsory since the
early 1950s, and the reporting has been almost complete and of
high quality (Cancer Registry of Norway, 2007). Medical Birth
Registry of Norway is also based on compulsory notification of
every birth or late abortion from 16 weeks of gestation onwards.
Medical Birth Registry of Norway includes demographic informa-
tion on the parents, the mother’s health before and during
pregnancy, complications during pregnancy and delivery, length of
pregnancy as well as information on the infant, including birth
defects and other perinatal problems (Irgens, 2000).
Within these data sources, we created a large study cohort of 2.1
million children, with a mean follow-up time of almost 12 years, to
study the relations between pre- and perinatal factors and
neuroblastoma. Nevertheless, only 178 cases were diagnosed,
illustrating the rarity of this tumour. Although some estimates
different from unity were discovered, the CIs were wide.
In general, children with congenital malformations have an
increased risk of cancer (Bjørge et al, 2008). In our data, there was
an increased risk of neuroblastoma in children with any congenital
abnormality. A recent report from the Children’s Oncology Group
study showed an increased neuroblastoma risk with increasing
number of congenital malformations, particularly genitourinary
and cardiac anomalies (Menegaux et al, 2005). Similar findings
were reported from the California Cancer Registry study (Urayama
et al, 2007). Also other birth defects have been associated with the
risk of neuroblastoma (Narod et al, 1997). The malformations
diagnosed in the eight neuroblastoma cases in our study had the
following organ system distribution: heart and blood vessels (one),
lip and palate (one), digestive system (two), urinary organs (one),
musculoskeletal system (two) and multiple abnormalities (one).
The literature dealing with pre- and perinatal risk factors for
neuroblastoma has been largely inconclusive (Hamrick et al, 2001;
Table 1 (Continued)
Adrenal medulla Non-adrenal All
Total no. of
N RR (95% CI) N RR (95% CI) N RR (95% CI) person-years
a
Pre-eclampsia
No 80 1.0 Referent 92 1.0 Referent 172 1.0 Referent 24639244
Yes 3 1.3 (0.4–4.2) 3 1.2 (0.4–3.7) 6 1.2 (0.5–2.8) 663616
Caesarean section
No 75 1.0 Referent 87 1.0 Referent 162 1.0 Referent 23362347
Yes 8 1.2 (0.6–2.4) 8 1.0 (0.5–2.1) 16 1.1 (0.6–1.8) 1940514
Paternal age (years)
o25 13 1.1 (0.5–2.1) 22 1.6 (0.9–2.8) 35 1.3 (0.9–2.1) 4343748
25–29 33 1.3 (0.8–2.3) 24 0.8 (0.5–1.5) 57 1.1 (0.7–1.6) 8468047
30–34 22 1.0 Referent 25 1.0 Referent 47 1.0 Referent 6959181
35–39 7 0.6 (0.3–1.5) 18 1.4 (0.8–2.6) 25 1.0 (0.6–1.7) 3428839
40+ 5 0.8 (0.3–2.2) 4 0.6 (0.2–1.7) 9 0.7 (0.3–1.4) 1886960
Test for trend P¼0.2 P¼0.3 P¼0.09
aThe total number of person-years for some variables may differ due to missing data.
bHead circumference has been recorded since 1978.
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case-control studies from the US have, however, suggested that
certain perinatal factors may be associated with risk. In a study
from birth and cancer registries in Minnesota, a maternal history
of one fetal loss, maternal drug use and small size for gestational
age were associated with neuroblastoma (Johnson et al, 2008). In a
study from the California Cancer Registry, associations with a
number of birth characteristics were observed, including child’s
race/ethnicity, gestational age/birth weight, caesarean section
delivery and maternal pregnancy history (Urayama et al, 2007).
In another study from the New York State Cancer Registry, pre-
and post-term gestations were associated with a significant
reduction in risk of neuroblastoma (Buck et al, 2001).
In mothers having pre-eclampsia during pregnancy, we found
an increased risk of borderline significance in children below the
age of 18 months. However, no strong associations have previously
been found with diseases/conditions during pregnancy, as pre-
eclampsia (Buck et al, 2001; Hamrick et al, 2001).
In summary, in a huge population-based cohort study, we found
that certain birth and parental characteristics may influence the
risk of neuroblastoma, but no strong associations were established.
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